>
Switch to:

Turning Point Therapeutics EV-to-EBITDA

: -15.52 (As of Today)
View and export this data going back to 2019. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Turning Point Therapeutics's enterprise value is $2,474.73 Mil. Turning Point Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was $-159.44 Mil. Therefore, Turning Point Therapeutics's EV-to-EBITDA for today is -15.52.

NAS:TPTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.07   Med: -27.15   Max: -14.34
Current: -15.51

-32.07
-14.34

During the past 4 years, the highest EV-to-EBITDA of Turning Point Therapeutics was -14.34. The lowest was -32.07. And the median was -27.15.

NAS:TPTX's EV-to-EBITDA is ranked lower than
99.99% of the 286 Companies
in the Biotechnology industry.

( Industry Median: 28.77 vs. NAS:TPTX: -15.51 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2021-04-19), Turning Point Therapeutics's stock price is $73.110000. Turning Point Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $-3.95. Therefore, Turning Point Therapeutics's PE Ratio for today is .

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Turning Point Therapeutics EV-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Annual Data
Dec17 Dec18 Dec19 Dec20
EV-to-EBITDA 0.00 0.00 -24.07 -30.18

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.07 -9.88 0.00 0.00 -30.18

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Turning Point Therapeutics EV-to-EBITDA Distribution

* The bar in red indicates where Turning Point Therapeutics's EV-to-EBITDA falls into.



Turning Point Therapeutics EV-to-EBITDA Calculation

Turning Point Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2474.731/-159.443
=-15.52

Turning Point Therapeutics's current Enterprise Value is $2,474.73 Mil.
Turning Point Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was -62.038 (Mar. 2020 ) + -32.138 (Jun. 2020 ) + -17.935 (Sep. 2020 ) + -47.332 (Dec. 2020 ) = $-159.44 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.


Turning Point Therapeutics  (NAS:TPTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Turning Point Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=73.110000/-3.95
=

Turning Point Therapeutics's share price for today is $73.110000.
Turning Point Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was -1.69 (Mar. 2020 ) + -0.82 (Jun. 2020 ) + -0.42 (Sep. 2020 ) + -1.02 (Dec. 2020 ) = $-3.95.

* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Turning Point Therapeutics EV-to-EBITDA Related Terms


Turning Point Therapeutics EV-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)